PRESS RELEASE published on 10/21/2024 at 20:00, 2 years ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 2 years 2 months ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 2 years 2 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 2 years 2 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 2 years 2 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 2 years 4 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
BRIEF published on 07/01/2024 at 09:27, 2 years 4 months ago ABIONYX finalise avec succès une augmentation de capital de 3,4 millions d'euros Augmentation De Capital Actions Et Bons De Souscription Biotechnologies ABIONYX Développement De La Septicémie
PRESS RELEASE published on 07/01/2024 at 09:22, 2 years 4 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 2 years 4 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
BRIEF published on 06/27/2024 at 19:27, 2 years 4 months ago ABIONYX Pharma obtient l'approbation unanime de l'Assemblée Générale Mixte Actionnaires Assemblée Générale Resolutions Biotechnologies ABIONYX Pharma
Published on 11/12/2026 at 15:55, 1 hour 21 minutes ago DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
Published on 11/12/2026 at 14:31, 2 hours 45 minutes ago First Breach Inc. Announces Third Quarter 2026 Earnings Conference Call
Published on 11/12/2026 at 14:00, 3 hours 16 minutes ago GameSquare Announces Peaky Blinders Digital Fan Experience, Advancing the Company's IP Monetization Strategy
Published on 11/12/2026 at 14:00, 3 hours 16 minutes ago NuRAN Wireless Highlights Recurring Revenue Economics and Growth Potential of Its 5,092-Tower Contracted NaaS Portfolio
Published on 11/12/2026 at 13:45, 3 hours 31 minutes ago Amarc and Freeport Successfully Complete 2026 Joy Copper-Gold District Exploration Program
Published on 11/12/2026 at 16:40, 36 minutes ago Rockwell Automation Introduces LogixEdge Controllers for Software-Defined Automation
Published on 11/12/2026 at 16:29, 47 minutes ago Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice
Published on 11/12/2026 at 16:06, 1 hour 10 minutes ago Leadership change at GEA: Klaus Stojentin to succeed Stefan Klebert as CEO
Published on 11/12/2026 at 16:05, 1 hour 11 minutes ago Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
Published on 11/12/2026 at 16:05, 1 hour 11 minutes ago EQS-Adhoc: GEA Group Aktiengesellschaft: Stefan Klebert to leave the Executive Board of GEA Group Aktiengesellschaft after the 2027 Annual General Meeting; his successor will be Klaus Stojentin
Published on 11/12/2026 at 08:56, 8 hours 19 minutes ago Number of shares and voting rights - October 2026 (In French only)
Published on 11/12/2026 at 08:56, 8 hours 19 minutes ago Nombre total d'actions et droits de vote - octobre 2026
Published on 11/12/2026 at 08:40, 8 hours 36 minutes ago FREY forms a €400 million equity partnership with GIC to invest in premium European retail parks
Published on 11/12/2026 at 08:40, 8 hours 36 minutes ago FREY et GIC s’associent pour investir 400 M€ de capital dans les retail parks premium en Europe
Published on 11/10/2026 at 18:00, 1 day 23 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
